Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,045 | 15 | 50.9% |
| Consulting Fee | $26,985 | 12 | 45.7% |
| Travel and Lodging | $1,190 | 5 | 2.0% |
| Food and Beverage | $719.44 | 11 | 1.2% |
| Education | $46.91 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $49,165 | 30 | $0 (2024) |
| Novo Nordisk Inc | $9,265 | 4 | $0 (2019) |
| ITI, Inc. | $266.97 | 5 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $135.79 | 2 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $90.71 | 1 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $45.59 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $16.60 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,688 | 1 | Novo Nordisk AS ($1,688) |
| 2023 | $4,469 | 4 | Novo Nordisk AS ($4,313) |
| 2022 | $17,126 | 8 | Novo Nordisk AS ($17,075) |
| 2021 | $4,693 | 7 | Novo Nordisk AS ($4,590) |
| 2020 | $2,380 | 2 | Novo Nordisk AS ($2,380) |
| 2019 | $9,265 | 4 | Novo Nordisk Inc ($9,265) |
| 2018 | $6,256 | 5 | Novo Nordisk AS ($6,120) |
| 2017 | $13,109 | 13 | Novo Nordisk AS ($13,000) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2024 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,687.50 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 11/16/2023 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $2,062.50 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 07/28/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: PSYCHIATRY | ||||||
| 02/23/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $130.75 | General |
| Category: PSYCHIATRY | ||||||
| 01/01/2023 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $2,250.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/24/2022 | Novo Nordisk AS | Saxenda (Drug) | — | In-kind items and services | $7,780.98 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/24/2022 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $5,355.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/24/2022 | Novo Nordisk AS | Saxenda (Drug) | — | In-kind items and services | $271.74 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/24/2022 | Novo Nordisk AS | Saxenda (Drug) | — | In-kind items and services | $96.92 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/20/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: PSYCHIATRY | ||||||
| 07/06/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Neuropsychiatry | ||||||
| 02/01/2022 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $850.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 01/01/2022 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $2,720.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/05/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA, INVEGA | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Neuroscience | ||||||
| 09/01/2021 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,020.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 06/01/2021 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $39.62 | General |
| Category: PSYCHIATRY | ||||||
| 04/12/2021 | ITI, Inc. | CAPLYTA (Drug) | Education | In-kind items and services | $46.91 | General |
| Category: PSYCHIATRY | ||||||
| 02/18/2021 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,190.00 | Research |
| Study: NN8022-4179 • Category: Obesity | ||||||
| 02/01/2021 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,360.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 02/01/2021 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,020.00 | Research |
| Study: NN8022-4392 • Category: Obesity | ||||||
| 10/14/2020 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,360.00 | Research |
| Study: NN8022-4432 • Category: Obesity | ||||||
| 04/06/2020 | Novo Nordisk AS | Saxenda (Drug) | — | Cash or cash equivalent | $1,020.00 | Research |
| Study: NN8022-4432 • Category: Obesity | ||||||
| 11/21/2019 | Novo Nordisk Inc | Saxenda (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: Obesity | ||||||
| 09/24/2019 | Novo Nordisk Inc | Saxenda (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: Obesity | ||||||
| 06/04/2019 | Novo Nordisk Inc | Saxenda (Drug) | Consulting Fee | Cash or cash equivalent | $1,360.00 | General |
| Category: Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN8022-4392 | Novo Nordisk AS | $26,475 | 12 |
| NN8022-4432 | Novo Nordisk AS | $2,380 | 2 |
| NN8022-4179 | Novo Nordisk AS | $1,190 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 24 | 26 | $5,714 | $2,092 |
| 2020 | 4 | 55 | 169 | $20,850 | $8,035 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 12 | $3,600 | $1,274 | 35.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 13 | 14 | $2,114 | $818.58 | 38.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 12 | 105 | $9,030 | $3,435 | 38.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 35 | $5,355 | $2,093 | 39.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 14 | $4,200 | $1,606 | 38.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 14 | 15 | $2,265 | $901.16 | 39.8% |
About Dr. Barbara Gracious, M.D
Dr. Barbara Gracious, M.D is a Psychiatry healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275579088.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barbara Gracious, M.D has received a total of $58,986 in payments from pharmaceutical and medical device companies, with $1,688 received in 2024. These payments were reported across 44 transactions from 7 companies. The most common payment nature is "" ($30,045).
As a Medicare-enrolled provider, Gracious has provided services to 79 Medicare beneficiaries, totaling 195 services with total Medicare billing of $10,127. Data is available for 2 years (2020–2021), covering 6 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Other Specialties Child & Adolescent Psychiatry
- Location Columbus, OH
- Active Since 06/21/2006
- Last Updated 02/01/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1275579088
Products in Payments
- Saxenda (Drug) $52,310
- Victoza (Drug) $6,120
- CAPLYTA (Drug) $266.97
- INGREZZA (Drug) $135.79
- INVEGA SUSTENNA (Drug) $16.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Columbus
Fred Romeo, Md, MD
Psychiatry — Payments: $2.3M
Michael Saribalas
Psychiatry — Payments: $1.3M
Kevin Ware, Md, MD
Psychiatry — Payments: $1.1M
Dr. Peter Zafirides, Md, MD
Psychiatry — Payments: $127,832
Dr. Benjamin Roy, M.d, M.D
Psychiatry — Payments: $102,125
Dr. Pavan Dontineni, M.d, M.D
Psychiatry — Payments: $32,829